Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of BLB101 in advanced solid tumors
CTR20263354Phase 2Active
- Sponsor
- Baylink Biosciences
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BLB-101 in Nonhematologic neoplasms, sponsored by Baylink Biosciences. Started Sep 2026; status: active.
02
Drugs
BLB-101
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20263354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263354.